This invention relates to a method for producing an alkenyl 1-aminocyclopropane-1-carboxylic acid of Formula I wherein R.sup.1 is a protecting group, n is an integer between 1 and 10, and A and B are chiral centres such that when A is S, B is R and when A is R, B is S. The method comprises a stereoselective formation of the cyclopropane moiety by cycloaddition onto a double bond, in a molecule comprising a chiral template, Formula lc. Further provided is the use of Formula I in the production of stapled peptides.

##STR00001##

A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to -melanocortin stimulating hormone (-MSH).

A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to ?-melanocortin stimulating hormone (?-MSH).

The invention relates to the application of peptides that can self-assemble to form supramolecular nanofibrils and hydrogels, hydrogel compositions containing the self-assembled supramolecular nanofibrils, and methods of uses and making the hydrogel compositions.

A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to ?-melanocortin stimulating hormone (?-MSH).

Disclosed are amino acid mimetics that possess antibiotic properties in prokaryotic cells. These mimetics are coupled to one or more optionally substituted amino acids provided that at least one of the amino acids is an optionally substituted amino acid selected from the group consisting of phenylglycine, tryptophan, phenylalanine, histidine, and tyrosine.

A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to ?-melanocortin stimulating hormone (?-MSH).

The invention relates to peptides with the following general formula:

A-Thr-Lys-Pro-B-C-D-X, where:

A0, Met, Met (O), Thr, Ala, His, Phe, Lys, Gly
B0, Gly, Asp, Trp, Gln, Asn, Tyr, Pro, Arg
C0, Arg, Phe, Tyr, Gly, His, Pro, Lys
D0, Val, Gly, Tyr, Trp, Phe, His
XOH, OCH.sub.3, NH.sub.2,
where 0 is no amino acid residue, provided that if A0, then B and/or C and/or D0, if B0, then C and/or D0,
excluding the peptides Phe-Thr-Lys-Pro-Gly (SEQ ID NO: 1), Thr-Lys-Pro-Pro-Arg (SEQ ID NO: 2), Thr-Lys-Pro-Arg-Gly (SEQ ID NO: 3).

The invention relates to the application of peptides that can self-assemble to form supramolecular nanofibrils and hydrogels, hydrogel compositions containing the self-assembled supramolecular nanofibrils, and methods of uses and making the hydrogel compositions.

Certain embodiments of the invention provide new compounds, conjugates, and salts as described herein that may inhibit and/or degrade PIN1. Also described methods of inhibiting and/or degrading PIN1 and methods of treating a PIN1 associated disease, and methods of developing degrader compounds for a target protein.